Open access Journal SINTA 1
Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial
ACTA MEDICA INDONESIANA · Vol. 58 No. 3 (2026)
- ISSN
- 2338-2732, 0125-9326
- Published
- 2026-10-07
- Publisher
- The Indonesian Society of Internal Medicine
- Language
- eng
Abstract
Background: Patients with chronic kidney disease undergoing hemodialysis are at risk of hepatitis C virus exposure due to nosocomial transmission and the duration of hemodialysis. The treatment for hepatitis C in patients with chronic kidney disease undergoing hemodialysis is oral direct-acting antiviral (DAA) therapy, which works directly as an antiviral. Currently, the DAA considered safe for use in patients with chronic kidney disease is grazoprevir/elbasvir. However, this DAA is expensive and effective in patients with genotypes 1 and 4. Recent studies have shown that sofosbuvir-based regimens are safe. Therefore, this study aimed to compare the efficacy and safety of sofosbuvir/daclatasvir with grazoprevir/elbasvir in patients with chronic hepatitis C undergoing hemodialysis. Methods: We conducted a multicenter, single-blind, randomized clinical trial that included 120 treatment-naïve, HCV-infected hemodialysis patients. We randomized only participants with fibrosis < F4. Patients with cirrhosis (F4) were assigned to sofosbuvir/daclatasvir per guideline-based contraindications for grazoprevir/elbasvir. Participants received sofosbuvir/daclatasvir or grazoprevir/elbasvir. The primary endpoints were sustained virologic response at week 12 (SVR12) and treatment-related adverse events. Statistical comparisons were conducted using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Results: 120 patients completed the study, with no dropouts or missing SVR12 data. All patients (100%) achieved SVR12 in both treatment groups. Sofosbuvir/daclatasvir and grazoprevir/elbasvir achieved 100% SVR at 12 weeks, with good safety and no adverse events in 98.3% of patients. Conclusion: Both sofosbuvir/daclatasvir and grazoprevir/elbasvir are highly effective and safe for treating hepatitis C in patients undergoing hemodialysis. Sofosbuvir/daclatasvir offers broader applicability across all fibrosis stages and genotypes, with substantially lower treatment costs.
Keywords
Collaboration network of the authors
40 authors · 239 co-authorship links · showing the 40 most connected
Hover or tap a name to highlight its co-authors. Double-click to open the author's page.
- University of Indonesia
- Affiliation unknown
- Different organisations
- Same organisation
- Affiliation unknown
- Thicker line = more joint articles · bigger circle = more articles
Show as table
| Co-author | Organisation | Joint articles |
|---|---|---|
| Juferdy Kurniawan | Affiliation unknown | 9 |
| Irsan Hasan | Affiliation unknown | 7 |
| Rino Alvani Gani | Affiliation unknown | 6 |
| Hamzah Shatri | Affiliation unknown | 5 |
| Chyntia Olivia Maurine Jasirwan | Affiliation unknown | 5 |
| Alvina Widhani | Affiliation unknown | 3 |
| Ika Prasetya Wijaya | Affiliation unknown | 3 |
| Cosmas Rinaldi A Lesmana | Affiliation unknown | 3 |
| Kemal Fariz Kalista | Affiliation unknown | 3 |
| Ikhwan Rinaldi | Affiliation unknown | 3 |
| Evy Yunihastuti | Affiliation unknown | 3 |
| Ni Made Hustrini | Affiliation unknown | 3 |
| Marcellus Simadibrata | Affiliation unknown | 3 |
| Cosmas Rinaldi Adithya Lesmana | Affiliation unknown | 3 |
| Eka Surya Nugraha | Affiliation unknown | 2 |
| Siti Aminah Abdurachman | Affiliation unknown | 2 |
| Kuntjoro Harimurti | Affiliation unknown | 2 |
| Aida Lydia | Affiliation unknown | 2 |
| Suhardjono Suhardjono | Affiliation unknown | 2 |
| Em Yunir | University of Indonesia | 2 |
| Maruhum Bonar H Marbun | Affiliation unknown | 2 |
| Maruhum Bonar Hasiholan Marbun | Affiliation unknown | 2 |
| Dadang Makmun | Affiliation unknown | 2 |
| Murdani Abdullah | Affiliation unknown | 2 |
| Adityo Susilo | Affiliation unknown | 2 |
| Nenny Agustanti | Affiliation unknown | 2 |
| Gita Aprilicia | Affiliation unknown | 2 |
| Sally Aman Nasution | Affiliation unknown | 2 |
Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.